UBS Group’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $186M | Sell |
298,234
-1,745
| -0.6% | -$1.19M | 0.02% | 713 |
|
|
2026
Q1 | $232M | Buy |
299,979
+28,821
| +11% | +$22.1M | 0.03% | 548 |
|
|
2025
Q4 | $209M | Sell |
271,158
-68,331
| -20% | -$46.4M | 0.03% | 554 |
|
|
2025
Q3 | $191M | Buy |
339,489
+45,974
| +16% | +$26M | 0.03% | 614 |
|
|
2025
Q2 | $154M | Buy |
293,515
+6,352
| +2% | +$3.55M | 0.03% | 674 |
|
|
2025
Q1 | $182M | Sell |
287,163
-95,672
| -25% | -$65.8M | 0.03% | 561 |
|
|
2024
Q4 | $273M | Buy |
382,835
+110,985
| +41% | +$93.1M | 0.05% | 374 |
|
|
2024
Q3 | $286M | Buy |
271,850
+17,389
| +7% | +$19.4M | 0.06% | 293 |
|
|
2024
Q2 | $267M | Sell |
254,461
-3,020
| -1% | -$2.93M | 0.07% | 276 |
|
|
2024
Q1 | $248M | Buy |
257,481
+122,544
| +91% | +$117M | 0.06% | 301 |
|
|
2023
Q4 | $119M | Buy |
134,937
+30,517
| +29% | +$25.1M | 0.04% | 503 |
|
|
2023
Q3 | $85.9M | Sell |
104,420
-56,022
| -35% | -$44M | 0.03% | 564 |
|
|
2023
Q2 | $115M | Buy |
160,442
+58,598
| +58% | +$45.2M | 0.04% | 440 |
|
|
2023
Q1 | $83.7M | Sell |
101,844
-37,451
| -27% | -$28.2M | 0.03% | 526 |
|
|
2022
Q4 | $100M | Buy |
139,295
+88,154
| +172% | +$65M | 0.04% | 489 |
|
|
2022
Q3 | $35.2M | Sell |
51,141
-73,182
| -59% | -$46.1M | 0.02% | 900 |
|
|
2022
Q2 | $73.5M | Buy |
124,323
+18,975
| +18% | +$12.3M | 0.03% | 553 |
|
|
2022
Q1 | $73.6M | Sell |
105,348
-83,823
| -44% | -$53M | 0.02% | 647 |
|
|
2021
Q4 | $119M | Sell |
189,171
-16,706
| -8% | -$10.3M | 0.03% | 528 |
|
|
2021
Q3 | $125M | Buy |
205,877
+48,150
| +31% | +$29.9M | 0.04% | 460 |
|
|
2021
Q2 | $88.1M | Sell |
157,727
-760
| -0.5% | -$385K | 0.03% | 566 |
|
|
2021
Q1 | $75M | Buy |
158,487
+18,922
| +14% | +$9.21M | 0.02% | 629 |
|
|
2020
Q4 | $67.4M | Buy |
139,565
+57,996
| +71% | +$31.3M | 0.02% | 642 |
|
|
2020
Q3 | $45.7M | Sell |
81,569
-45,315
| -36% | -$27.5M | 0.02% | 691 |
|
|
2020
Q2 | $79.1M | Buy |
126,884
+30,814
| +32% | +$17.5M | 0.03% | 436 |
|
|
2020
Q1 | $46.9M | Sell |
96,070
-24,372
| -20% | -$10.1M | 0.02% | 572 |
|
|
2019
Q4 | $45.2M | Sell |
120,442
-20,670
| -15% | -$6.95M | 0.02% | 835 |
|
|
2019
Q3 | $39.1M | Buy |
141,112
+33,692
| +31% | +$9.97M | 0.02% | 815 |
|
|
2019
Q2 | $33.6M | Sell |
107,420
-65,499
| -38% | -$21.8M | 0.01% | 889 |
|
|
2019
Q1 | $71M | Buy |
172,919
+67,585
| +64% | +$27.8M | 0.03% | 479 |
|
|
2018
Q4 | $39.3M | Sell |
105,334
-16,215
| -13% | -$5.93M | 0.02% | 709 |
|
|
2018
Q3 | $49.1M | Buy |
121,549
+23,021
| +23% | +$8.76M | 0.02% | 681 |
|
|
2018
Q2 | $34M | Buy |
98,528
+12,366
| +14% | +$3.87M | 0.01% | 860 |
|
|
2018
Q1 | $29.7M | Sell |
86,162
-50,582
| -37% | -$17.6M | 0.01% | 906 |
|
|
2017
Q4 | $51.4M | Buy |
136,744
+43,872
| +47% | +$17.8M | 0.02% | 655 |
|
|
2017
Q3 | $41.5M | Buy |
92,872
+29,959
| +48% | +$14.3M | 0.02% | 690 |
|
|
2017
Q2 | $30.9M | Buy |
62,913
+7,454
| +13% | +$3.26M | 0.02% | 802 |
|
|
2017
Q1 | $21.5M | Buy |
55,459
+14,550
| +36% | +$5.39M | 0.01% | 992 |
|
|
2016
Q4 | $15M | Buy |
40,909
+3,082
| +8% | +$1.17M | 0.01% | 1210 |
|
|
2016
Q3 | $15.2M | Buy |
37,827
+5,918
| +19% | +$2.37M | 0.01% | 1140 |
|
|
2016
Q2 | $11.1M | Buy |
31,909
+2,281
| +8% | +$878K | 0.01% | 1297 |
|
|
2016
Q1 | $10.7M | Sell |
29,628
-41,694
| -58% | -$17.2M | 0.01% | 1289 |
|
|
2015
Q4 | $38.7M | Buy |
71,322
+17,101
| +32% | +$9.27M | 0.03% | 606 |
|
|
2015
Q3 | $25.2M | Sell |
54,221
-27,399
| -34% | -$14.7M | 0.02% | 764 |
|
|
2015
Q2 | $41.6M | Sell |
81,620
-6,372
| -7% | -$3.11M | 0.03% | 593 |
|
|
2015
Q1 | $39.7M | Sell |
87,992
-10,512
| -11% | -$4.46M | 0.03% | 597 |
|
|
2014
Q4 | $40.4M | Buy |
+98,504
| New | +$38.7M | 0.03% | 626 |
|
Other funds holding REGN
UBS Group's REGN Position: Q2 2026 in Review
UBS Group reduced its Regeneron Pharmaceuticals (REGN) stake by 0.58% in Q2 2026, selling an estimated $1.19M and leaving 298,234 shares worth $186M. The position accounts for 0.02% of the portfolio, ranked #713.
UBS Group first reported a position in REGN in Q4 2014 and has held it in 47 quarters since. The position peaked at $286M in Q3 2024. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- UBS Group held 298,234 shares of Regeneron Pharmaceuticals worth $186M as of Q2 2026.
- UBS Group sold 1,745 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $1.19M.
- Regeneron Pharmaceuticals made up 0.02% of UBS Group's portfolio in Q2 2026, its #713 holding.
- UBS Group first reported a position in Regeneron Pharmaceuticals in Q4 2014 and has held it in 47 quarters since.
- UBS Group's Regeneron Pharmaceuticals position peaked at $286M in Q3 2024.
- 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.